Cannabis sativa is the most used recreational drug worldwide. In recent years, there has been a growing interest in the potential therapeutic benefits of medicinal cannabis to treat a variety of psychiatric and neurological conditions. In particular, cannabidiol (CBD), a nonpsychoactive cannabis constituent, has been investigated for its potential prosocial effects on behavior, although the molecular mechanisms underlying this effect are still largely unknown. The aim of this study was to investigate the effect of a C. sativa oil CBD rich (CS oil) on social interaction and ultrasonic communication in mice.
Study Design:
Twenty-seven adult male mice (B6; 129P F2) were treated daily with vehicle or CS oil for 2 weeks. At Day 14, mice were tested for behavior (social interaction test and ultrasonic communication). Forty minutes before the behavioral tests, mice were exposed to intranasal treatment with vehicle or the oxytocin receptor antagonist, L-371,257. After behavioral tests, VH- and CS oil-treated mice were sacrificed, RNA was extracted from the hypothalamus and used for quantitative Real Time-PCR experiments.
Results:
We found that a 2-week treatment with the CS oil on mice exerted a prosocial effect associated with an increase in ultrasonic vocalizations. These effects were inhibited by pretreating mice with an oxytocin receptor antagonist. In addition, at the molecular level, we found that CS oil treatment caused a significant increase in oxytocin and a decrease in oxytocin receptor expression levels in the brain hypothalamus.
Conclusion:
Our results suggest that CS oil promotes social behavior by acting on oxytocin pathway.
Get full access to this article
View all access options for this article.
References
1.
AshtonCH. Adverse effects of cannabis and cannabinoids. Br J Anaesth. 1999; 83(4):637–649; doi: 10.1093/bja/83.4.637
2.
PellatiF, BorgonettiV, BrighentiV, et al.Cannabis sativa L. and nonpsychoactive cannabinoids: Their chemistry and role against oxidative stress, inflammation, and cancer. Biomed Res Int. 2018; 2018:1691428; doi: 10.1155/2018/1691428
3.
ChallenerC. Synthesis, extraction, and purification of cannabinoids. Pharmaceutical Technol. 2022; 46:22–25.
4.
LuHC, MackieK. An introduction to the endogenous cannabinoid system. Biol Psychiatry. 2016; 79(7):516–525; doi: 10.1016/j.biopsych.2015.07.028
5.
HäuserW, FitzcharlesMA, RadbruchL, et al.Cannabinoids in pain management and palliative medicine. Dtsch Arztebl Int. 2017; 114(38):627–634; doi: 10.3238/arztebl.2017.0627
6.
KlecknerAS, KlecknerIR, KamenCS, et al.Opportunities for cannabis in supportive care in cancer. Ther Adv Med Oncol. 2019; 11:1758835919866362; doi: 10.1177/1758835919866362
7.
ThamM, YilmazO, AlaverdashviliM, et al.Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors. Br J Pharmacol. 2019; 176(10):1455–1469; doi: 10.1111/bph.14440
8.
LaprairieRB, BagherAM, KellyME, et al.Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015; 172(20):4790–4805; doi: 10.1111/bph.13250
9.
Martínez-PinillaE, VaraniK, Reyes-ResinaI, et al.Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB2 Receptors. Front Pharmacol. 2017; 8:744; doi: 10.3389/fphar.2017.00744
10.
ZuardiAW. 2017. The anxiolytic effects of cannabidiol (CBD). In: Biology, Pharmacology, Diagnosis, and Treatment, pp. e131–e139; doi: 10.1016/B978-0-12-800,756-3.00097-1
11.
AtalayS, Jarocka-KarpowiczI, SkrzydlewskaE. Antioxidative and anti-inflammatory properties of cannabidiol. Antioxidants (Basel). 2019; 9(1):21; doi: 10.3390/antiox9010021
12.
MassiP, SolinasM, CinquinaV, et al.Cannabidiol as potential anticancer drug. Br J Clin Pharmacol. 2013; 75(2):303–312; doi: 10.1111/j.1365-2125.2012.04298.x
13.
BursteinS. Cannabidiol (CBD) and its analogs: A review of their effects on inflammation. Bioorg Med Chem. 2015; 23(7):1377–1385; doi: 10.1016/j.bmc.2015.01.059
14.
BonaccorsoS, RicciardiA, ZanganiC, et al.Cannabidiol (CBD) use in psychiatric disorders: A systematic review. Neurotoxicology. 2019; 74:282–298; doi: 10.1016/j.neuro.2019.08.002
15.
PremoliM, AriaF, BoniniSA, et al.Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment. Life Sci. 2019; 224:120–127; doi: 10.1016/j.lfs.2019.03.053
16.
WhiteCM. A review of human studies assessing cannabidiol’s (CBD) therapeutic actions and potential. J Clin Pharmacol. 2019; 59(7):923–934; doi: 10.1002/jcph.1387
17.
OsborneAL, SolowijN, BabicI, et al.Improved social interaction, recognition and working memory with cannabidiol treatment in a prenatal infection (poly I:C) rat model. Neuropsychopharmacology. 2017; 42(7):1447–1457; doi: 10.1038/npp.2017.40
18.
AranA, CassutoH, LubotzkyA, et al.Brief Report: Cannabidiol-rich cannabis in children with autism spectrum disorder and severe behavioral problems—A retrospective feasibility study. J Autism Dev Disord. 2019; 49(3):1284–1288; doi: 10.1007/s10803-018-3808-2
19.
Fleury-TeixeiraP, CaixetaFV, Ramires da SilvaLC, et al.Effects of CBD-enriched cannabis sativa extract on autism spectrum disorder symptoms: An observational study of 18 participants undergoing compassionate use. Front Neurol. 2019; 10:1145; doi: 10.3389/fneur.2019.01145
20.
ParrellaNF, HillAT, EnticottPG, et al.A systematic review of cannabidiol trials in neurodevelopmental disorders. Pharmacol Biochem Behav. 2023; 230:173607; doi: 10.1016/j.pbb.2023.173607
21.
MastinuA, AscrizziR, RibaudoG, et al.Prosocial effects of nonpsychotropic Cannabis sativa in mice. Cannabis Cannabinoid Res. 2022; 7(2):170–178; doi: 10.1089/can.2021.0017
22.
StabenJ, KochM, ReidK, et al.Cannabidiol and cannabis-inspired terpene blends have acute prosocial effects in the BTBR mouse model of autism spectrum disorder. Front Neurosci. 2023; 17:1185737; doi: 10.3389/fnins.2023.1185737
23.
BertoniA, SchallerF, TyzioR, et al.Oxytocin administration in neonates shapes hippocampal circuitry and restores social behavior in a mouse model of autism. Mol Psychiatry. 2021; 26(12):7582–7595; doi: 10.1038/s41380-021-01227-6
24.
FroemkeRC, YoungLJ. Oxytocin, neural plasticity, and social behavior. Annu Rev Neurosci. 2021; 44:359–381; doi: 10.1146/annurev-neuro-102320-102847
25.
MuscatelliF, MatarazzoV, ChiniB. Neonatal oxytocin gives the tempo of social and feeding behaviors. Front Mol Neurosci. 2022; 15:1071719; doi: 10.3389/fnmol.2022.1071719
26.
GrinevichV, Knobloch-BollmannHS, EliavaM, et al.Assembling the puzzle: Pathways of oxytocin signaling in the brain. Biol Psychiatry. 2016; 79(3):155–164; doi: 10.1016/j.biopsych.2015.04.013
27.
JurekB, NeumannID. The oxytocin receptor: From intracellular signaling to behavior. Physiol Rev. 2018; 98(3):1805–1908; doi: 10.1152/physrev.00031.2017
PeñagarikanoO, LázaroMT, LuXH, et al.Exogenous and evoked oxytocin restores social behavior in the Cntnap2 mouse model of autism. Sci Transl Med. 2015; 7(271):271ra8; doi: 10.1126/scitranslmed.3010257
30.
SilvermanJL, YangM, LordC, et al.Behavioural phenotyping assays for mouse models of autism. Nat Rev Neurosci. 2010; 11(7):490–502; doi: 10.1038/nrn2851
31.
AriaF, BoniniSA, CattaneoV, et al.Brain structural and functional alterations in mice prenatally exposed to LPS are only partially rescued by anti-inflammatory treatment. Brain Sci. 2020; 10(9):620; doi: 10.3390/brainsci10090620
PetroniV, SubashiE, PremoliM, et al.Autistic-like behavioral effects of prenatal stress in juvenile Fmr1 mice: The relevance of sex differences and gene-environment interactions. Sci Rep. 2022; 12(1):7269; doi: 10.1038/s41598-022-11083-1
34.
FykeW, PremoliM, Echeverry AlzateV, et al.Communication and social interaction in the cannabinoid-type 1 receptor null mouse: Implications for autism spectrum disorder. Autism Res. 2021; 14(9):1854–1872; doi: 10.1002/aur.2562
35.
PremoliM, PetroniV, BulthuisR, et al.Ultrasonic vocalizations in adult C57BL/6J Mice: The role of sex differences and repeated testing. Front Behav Neurosci. 2022; 16:883353; doi: 10.3389/fnbeh.2022.883353
36.
EgnorSR, SeagravesKM. The contribution of ultrasonic vocalizations to mouse courtship. Curr Opin Neurobiol. 2016; 38:1–5; doi: 10.1016/j.conb.2015.12.009
37.
HammerschmidtK, RadyushkinK, EhrenreichH, et al.The structure and usage of female and male mouse ultrasonic vocalizations reveal only minor differences. PLoS One. 2012; 7(7):e41133; doi: 10.1371/journal.pone.0041133
38.
SugimotoH, OkabeS, KatoM, et al.A role for strain differences in waveforms of ultrasonic vocalizations during male-female interaction. PLoS One. 2011; 6(7):e22093; doi: 10.1371/journal.pone.0022093
39.
ScattoniML, McFarlaneHG, ZhodzishskyV, et al.Reduced ultrasonic vocalizations in vasopressin 1b knockout mice. Behav Brain Res. 2008; 187(2):371–378; doi: 10.1016/j.bbr.2007.09.034
40.
GutkowskaJ, BroderickTL, BogdanD, et al.Downregulation of oxytocin and natriuretic peptides in diabetes: Possible implications in cardiomyopathy. J Physiol. 2009; 587(Pt 19):4725–4736; doi: 10.1113/jphysiol.2009.176461
41.
WeiD, DinhD, LeeD, et al.Enhancement of anandamide-mediated endocannabinoid signaling corrects autism-related social impairment. Cannabis Cannabinoid Res. 2016; 1(1):81–89; doi: 10.1089/can.2015.0008
42.
MastinuA, PremoliM, MaccarinelliG, et al.Melanocortin 4 receptor stimulation improves social deficits in mice through oxytocin pathway. Neuropharmacology. 2018; 133:366–374; doi: 10.1016/j.neuropharm.2018.02.007
43.
WeiD, LeeD, CoxCD, et al.Endocannabinoid signaling mediates oxytocin-driven social reward. Proc Natl Acad Sci U S A. 2015; 112(45):14084–14089; doi: 10.1073/pnas.1509795112
44.
PremoliM, BoniniSA, MastinuA, et al.Specific profile of ultrasonic communication in a mouse model of neurodevelopmental disorders. Sci Rep. 2019; 9(1):15912; doi: 10.1038/s41598-019-52378-0
45.
PremoliM, MemoM, BoniniSA. Ultrasonic vocalizations in mice: Relevance for ethologic and neurodevelopmental disorders studies. Neural Regen Res. 2021; 16(6):1158–1167; doi: 10.4103/1673-5374.300340
46.
PremoliM, PietropaoloS, WöhrM, et al.Mouse and rat ultrasonic vocalizations in neuroscience and neuropharmacology: State of the art and future applications. Eur J Neurosci. 2023; 57(12):2062–2096; doi: 10.1111/ejn.15957
47.
BarfieldRJ. The hypothalamus and social behavior with special reference to the hormonal control of sexual behavior. Poult Sci. 1979; 58(6):1625–1632; doi: 10.3382/ps.0581625
48.
HuRK, ZuoY, LyT, et al.An amygdala-to-hypothalamus circuit for social reward. Nat Neurosci. 2021; 24(6):831–842; doi: 10.1038/s41593-021-00828-2
49.
FerberSG, NamdarD, Hen-ShovalD, et al.The “entourage effect”: Terpenes coupled with cannabinoids for the treatment of mood disorders and anxiety disorders. Curr Neuropharmacol. 2020; 18(2):87–96; doi: 10.2174/1570159X17666190903103923
50.
LaVigneJE, HeckselR, KeresztesA, et al.Cannabis sativa terpenes are cannabimimetic and selectively enhance cannabinoid activity. Sci Rep. 2021; 11(1):8232; doi: 10.1038/s41598-021-87740-8
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
